Source:http://linkedlifedata.com/resource/pubmed/id/16932023
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-8-25
|
| pubmed:abstractText |
The growth rate of a tumor cell population depends on two major factors: the percentage of proliferating cells (cell growth fraction) and the rapidity of their duplication (cell proliferation rate). The authors evaluated the prognostic and predictive value of both kinetics parameters in a large series of breast cancer patients (n=504). The cell growth fraction was determined by MIB-1 immunostaining, the cell proliferation rate by AgNOR analysis. Ki-67 LI (labeling index) and AgNOR area were significantly associated with histotype, histologic grade, tumor size, estrogen/progesterone receptor status, patient age, and lymph node involvement (P<0.005). In the entire series of patients, both kinetics variables were significantly and independently associated with the clinical outcome, but their prognostic relevance was quite different when node-negative and node-positive patients were considered separately. Although in node-positive patients Ki-67 LI and AgNOR area were the unique independent predictors of disease-free and overall survival, they were excluded by the multivariate Cox model in node-negative patients, where only tumor size and estrogen receptor status retained a significant P-value. These results show that in breast carcinoma the cell growth fraction and the cell proliferation rate have a different prognostic impact with respect to the lymph node status and are major determinants of clinical outcome in node-positive patients only. Within this subgroup, the rapidity of cell proliferation as assessed by AgNOR analysis also served as a sensitive predictor of the response to adjuvant treatments.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1541-2016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
314-23
|
| pubmed:meshHeading |
pubmed-meshheading:16932023-Adult,
pubmed-meshheading:16932023-Aged,
pubmed-meshheading:16932023-Aged, 80 and over,
pubmed-meshheading:16932023-Breast Neoplasms,
pubmed-meshheading:16932023-Carcinoma,
pubmed-meshheading:16932023-Cell Proliferation,
pubmed-meshheading:16932023-Female,
pubmed-meshheading:16932023-Follow-Up Studies,
pubmed-meshheading:16932023-Humans,
pubmed-meshheading:16932023-Immunohistochemistry,
pubmed-meshheading:16932023-Lymph Nodes,
pubmed-meshheading:16932023-Middle Aged,
pubmed-meshheading:16932023-Multivariate Analysis,
pubmed-meshheading:16932023-Neoplasm Invasiveness,
pubmed-meshheading:16932023-Prognosis,
pubmed-meshheading:16932023-Proportional Hazards Models,
pubmed-meshheading:16932023-Survival Analysis,
pubmed-meshheading:16932023-Survival Rate,
pubmed-meshheading:16932023-Tumor Markers, Biological
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients.
|
| pubmed:affiliation |
Department of Experimental Pathology, Unit of Clinical Pathology, University of Bologna, Italy. davide.trere@unibo.it
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|